Business
Tesla Service Center In San Diego
(Kevin Carter/Getty Images)

What does the end of the $7,500 federal tax credit mean for Tesla’s finances?

Analyst Troy Teslike estimates what will happen to Tesla’s top and bottom lines in several different scenarios.

Rani Molla

When the $7,500 federal EV tax credit ends in September, Tesla will have some tough decisions to make, having to choose between denting sales or its bottom line. Now we have an idea of just how damaging that could be.

An analyst who goes by the name Troy Teslike recently modeled what Tesla’s finances for Q4 — the first quarter without the credit — might look like, depending on whether or how much Tesla lowers its prices.

If Tesla keeps prices as they are without the discount, effectively raising the price for buyers by $7,500 (scenario No. 1), he says Tesla could see its US sales plunge 37%, but the company’s gross margins would fall only to 13% and its earnings per share to $0.16 (down from 15% and $0.33 in Q2 2025, respectively).

The other end of the spectrum (scenario No. 8) would be if Tesla ate the $7,500 credit, keeping prices the same for consumers. In that case, Teslike estimates that deliveries wouldn’t drop, but the company’s margins and earnings would decline substantially to 8.1% and $0.03, respectively — barely a profit at all.

Teslike suspects the EV company will probably pick somewhere in the middle and cut the price for consumers by about $2,500.

Here’s what each of those scenarios would look like:

More Business

See all Business
Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.